Published in Antimicrob Agents Chemother on October 01, 2002
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol (2003) 1.39
Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis (2003) 0.92
Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother (2003) 0.89
Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 0.83
Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis. Antimicrob Agents Chemother (2005) 0.81
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res (1990) 3.24
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 2.74
In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother (2001) 2.03
Pentamidine: a review. Rev Infect Dis (1985) 1.87
Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) (1997) 1.83
In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother (2000) 1.61
Use of a new bioassay to study pentamidine pharmacokinetics. J Infect Dis (1985) 1.36
In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother (1984) 1.29
Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition. Antimicrob Agents Chemother (2000) 1.24
Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis (2001) 1.17
Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother (1998) 1.11
Effects of pentamidine isethionate on Saccharomyces cerevisiae. Antimicrob Agents Chemother (1994) 1.10
Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol (1998) 1.09
Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res (1998) 1.06
Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother (2002) 1.04
Distribution of pentamidine in patients with AIDS. J Infect Dis (1988) 1.02
Enhancement of the in vitro activity of amphotericin B against Aspergillus spp. by tetracycline analogs. Antimicrob Agents Chemother (1984) 1.01
Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species. Eur J Clin Microbiol Infect Dis (1997) 0.91
Effect of pentamidine on the growth of Cryptococcus neoformans. J Antimicrob Chemother (1994) 0.90
Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother (1990) 0.88
Current issues in the treatment and prophylaxis of Pneumocystis carinii pneumonia in HIV infection. J Antimicrob Chemother (1997) 0.84
Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs. Antimicrob Agents Chemother (2001) 0.84
The effect of nebulised pentamidine on the concentration of intra-oral Candida albicans in HIV-infected patients. J Med Microbiol (1994) 0.83
Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani. Acta Trop (1998) 0.81
Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob Agents Chemother (1998) 0.80
In vitro antimicrobial activity of aromatic diamidines and diimidazolines related to pentamidine. Eur J Med Chem (2001) 0.79
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis (2004) 3.02
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother (2007) 2.74
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol (2005) 2.36
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother (2002) 2.26
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 2.09
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
Azole-resistant central nervous system aspergillosis. Clin Infect Dis (2009) 1.94
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis (2003) 1.91
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis (2006) 1.79
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One (2010) 1.77
Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol (2002) 1.75
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis (2009) 1.73
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 1.71
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol (2006) 1.64
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis (2013) 1.59
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol (2003) 1.59
Multidrug resistance in Aspergillus fumigatus. N Engl J Med (2002) 1.54
Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol (2002) 1.49
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell (2008) 1.46
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother (2010) 1.45
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis (2008) 1.43
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol (2008) 1.43
Healthcare-associated mucormycosis. Clin Infect Dis (2012) 1.42
Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw (2006) 1.41
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2003) 1.40
Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol (2010) 1.37
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis (2005) 1.36
Molecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosa. J Clin Microbiol (2009) 1.36
Aspergillosis--and a misleading sensitivity result. Lancet (2007) 1.36
1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med (2006) 1.35
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol (2005) 1.34
Aspergillus species intrinsically resistant to antifungal agents. Med Mycol (2010) 1.33
Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol (2010) 1.33
Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis (2004) 1.33
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
Molecular identification of black-grain mycetoma agents. J Clin Microbiol (2006) 1.28
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother (2003) 1.28
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 1.25
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother (2009) 1.23
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One (2012) 1.22
Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis (2004) 1.22
Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids (2007) 1.22
Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health (2006) 1.22
Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother (2008) 1.17
Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol (2008) 1.17
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol (2006) 1.16
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol (2012) 1.16
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol (2003) 1.15
Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol (2011) 1.14
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 1.13
Utility of a microsatellite assay for identifying clonally related outbreak isolates of Aspergillus fumigatus. J Microbiol Methods (2008) 1.11
Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis. J Clin Microbiol (2007) 1.10
Microsatellite based typing of Aspergillus fumigatus: strengths, pitfalls and solutions. J Microbiol Methods (2007) 1.10
In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother (2004) 1.08
Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother (2003) 1.08
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother (2008) 1.07
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother (2009) 1.07
Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates. Antimicrob Agents Chemother (2006) 1.06
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother (2005) 1.06
Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol (2011) 1.05
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother (2002) 1.05
Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. Am J Respir Crit Care Med (2013) 1.05
In vitro susceptibilities of Zygomycota to polyenes. J Antimicrob Chemother (2002) 1.05
Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother (2006) 1.05
The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol (2011) 1.05
Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother (2002) 1.05